BioMarin Pharmaceutical Inc.
BMRN · Nasdaq
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B | $1.70B | $1.49B |
| Cost of Revenue | $717.44M | $580.24M | $532.06M | $503.02M | $470.51M | $524.27M | $359.47M | $315.26M |
| Research & Development | $921.93M | $747.18M | $746.77M | $649.61M | $628.79M | $628.12M | $715.01M | $696.33M |
| Selling, General & Administrative | $1.15B | $1.01B | $892.41M | $823.24M | $759.38M | $737.67M | $680.92M | $604.35M |
| Operating Expenses | $2.81B | $2.37B | $2.23B | $1.94B | $1.93B | $1.90B | $1.80B | $1.61B |
| Operating Income | $409.48M | $484.21M | $185.77M | $160.97M | -$82.34M | -$43.44M | -$100.46M | -$123.52M |
| Interest Expense | — | — | $17.34M | $15.97M | $15.34M | $29.31M | $23.46M | $43.66M |
| Income Before Taxes | $482.48M | $541.76M | $188.56M | $149.58M | -$75.35M | -$49.00M | -$94.81M | -$142.71M |
| Provision for Income Taxes | $133.58M | $114.90M | $20.92M | $8.02M | -$11.27M | -$903.03M | -$70.96M | -$65.49M |
| Net Income | $348.90M | $426.90M | $167.60M | $141.60M | -$64.10M | $854.03M | -$23.85M | -$77.21M |
| Basic EPS | $1.82 | $2.25 | $0.89 | $0.76 | -$0.35 | $4.72 | -$0.13 | -$0.44 |
| Diluted EPS | $1.80 | $2.21 | $0.87 | $0.75 | -$0.35 | $4.50 | -$0.13 | -$0.44 |
| Basic Shares Outstanding | 191.79M | 190.03M | 187.83M | 185.27M | 182.85M | 180.80M | 179.04M | 177.06M |
| Diluted Shares Outstanding | 197.39M | 196.71M | 191.59M | 188.96M | 182.85M | 191.68M | 179.04M | 177.27M |
Analyst Estimates
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Dec 2026 | $2.59 | $2.42 | $2.88 | 7 | ↑0 ↓6 |
| Dec 2027 | $5.31 | $3.30 | $6.47 | 9 | ↑1 ↓3 |
| Dec 2028 | $6.08 | $5.53 | $6.62 | 2 | ↑0 ↓2 |
